[1]韩 寒,陈雨晨,刘 洋,等.替雷利珠单抗治疗晚期非小细胞肺癌患者的真实世界研究[J].医学信息,2025,38(08):80-86.[doi:10.3969/j.issn.1006-1959.2025.08.016]
　HAN Han,CHEN Yuchen,LIU Yang,et al.A Real-world Study of Tislelizumab in the Treatment of Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2025,38(08):80-86.[doi:10.3969/j.issn.1006-1959.2025.08.016]
点击复制

替雷利珠单抗治疗晚期非小细胞肺癌患者的真实世界研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年08期
页码:
80-86
栏目:
论著
出版日期:
2025-04-15

文章信息/Info

Title:
A Real-world Study of Tislelizumab in the Treatment of Patients with Advanced Non-small Cell Lung Cancer
文章编号:
1006-1959（2025）08-0080-07
作者:
韩 寒; 陈雨晨; 刘 洋; 任芳芳; 王西勇
安徽医科大学附属宿州医院肿瘤内科，安徽 宿州 234000
Author(s):
HAN Han;  CHEN Yuchen;  LIU Yang;  REN Fangfang;  WANG Xiyong
Oncology Department, Suzhou Hospital of Anhui Medical University, Suzhou 234000, Anhui, China
关键词:
替雷利珠单抗; 非小细胞肺癌; 免疫治疗; 客观缓解率; 疾病控制率; 总生存期; 无进展生存期
Keywords:
Tislelizumab;  Non-small cell lung cancer;  Immunotherapy;  Objective remission rate;  Disease control rate;  Overall survival;  Progression-free survival
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2025.08.016
文献标志码:
A
摘要:
目的 探讨真实世界中替雷利珠单抗治疗晚期非小细胞肺癌的有效性和安全性。方法 纳入2020年1月-2023年10月在安徽医科大学附属宿州医院使用替雷利珠单抗治疗的晚期NSCLC患者，采集患者的基本临床特征及疗效、副反应等数据。采用Kaplan-Meier法进行生存分析，采用Cox风险回归模型进行多因素分析。结果 共纳入95例患者，最终中位PFS为5.43（95%CI：3.84~7.03）个月，中位OS为12.17（95%CI：7.72~16.62）个月，ORR和DCR分别为36.84%和66.32%。Kaplan-Meier单因素分析显示，转移部位、ECOG评分与患者PFS相关（P＜0.05），而转移部位、ECOG评分、治疗线数与患者OS相关（P＜0.05）。多因素分析显示，肺内转移、远处转移、ECOG评分、治疗线数是PFS的独立影响因素，肺内转移、ECOG评分、治疗线数是OS的独立影响因素。在安全性方面，患者对于替雷利珠单抗的耐受性良好，未见新的不良反应信号。结论 替雷利珠单抗具有肯定的抗肿瘤疗效，安全可控，可为晚期NSCLC患者带来临床获益。
Abstract:
Objective To investigate the efficacy and safety of tislelizumab in the treatment of advanced non-small cell lung cancer in the real world. Methods From January 2020 to October 2023, patients with advanced NSCLC treated with tislelizumab in Suzhou Hospital of Anhui Medical University were included. The basic clinical characteristics, efficacy and side effects of patients were collected. Kaplan-Meier method was used for survival analysis, and Cox risk regression model was used for multivariate analysis. Results A total of 95 patients were included. The final median PFS was 5.43(95%CI: 3.84-7.03) months, the median OS was 12.17(95%CI: 7.72-16.62) months, and the ORR and DCR were 36.84% and 66.32%, respectively. Kaplan-Meier univariate analysis showed that metastasis site and ECOG score were related to PFS (P<0.05), while metastasis site, ECOG score and treatment line number were related to OS (P<0.05). Multivariate analysis showed that intrapulmonary metastasis, distant metastasis, ECOG score and number of treatment lines were independent influencing factors of PFS, and intrapulmonary metastasis, ECOG score and number of treatment lines were independent influencing factors of OS. In terms of safety, the patient’s tolerance to tislelizumab was good, and no new adverse reaction signals were observed. Conclusion Tislelizumab has a definite anti-tumor effect, is safe and controllable, and can bring clinical benefits to patients with advanced NSCLC.

参考文献/References:

[1]Gao S,Li N,Wang S,et al.Lung Cancer in People’s Republic of China[J].J Thorac Oncol,2020,15(10):1567-1576.[2]Bade BC,Dela Cruz CS.Lung Cancer 2020:Epidemiology,Etiology,and Prevention[J].Clin Chest Med,2020,41(1):1-24.[3]Miller KD,Nogueira L,Devasia T,et al.Cancer treatment and survivorship statistics,2022[J].CA Cancer J Clin,2022,72(5):409-436.[4]Zhang QY,Wang FX,Jia KK,et al.Natural Product Interventions for Chemotherapy and Radiotherapy-Induced Side Effects[J].Front Pharmacol,2018,9:1253.[5]Markham MJ,Wachter K,Agarwal N,et al.Clinical Cancer Advances 2020:Annual Report on Progress Against Cancer From the American Society of Clinical Oncology[J].J Clin Oncol,2020,38(10):1081.[6]Liu SY,Wu YL.Tislelizumab:an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)[J].Expert Opin Investig Drugs,2020,29(12):1355-1364.[7]Zhang T,Song X,Xu L,et al.The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions[J].Cancer Immunol Immunother,2018,67(7):1079-1090.[8]Dahan R,Sega E,Engelhardt J,et al.FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis[J].Cancer Cell,2015,28(3):285-295.[9]Arlauckas SP,Garris CS,Kohler RH,et al.In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy[J].Sci Transl Med,2017,9(389):eaal3604.[10]Wang J,Lu S,Yu X,et al.Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer:A Phase 3 Randomized Clinical Trial[J].JAMA Oncol,2021,7(5):709-717.[11]Lu S,Wang J,Yu Y,et al.Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304):A Randomized Phase 3 Trial[J].J Thorac Oncol,2021,16(9):1512-1522.[12]Wang P,Fang X,Yin T,et al.Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study[J].Front Oncol,2021,11:628124.[13]Borghaei H,Paz-Ares L,Horn L,et al.Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer[J].N Engl J Med,2015,373(17):1627-1639.[14]Herbst RS,Baas P,Kim DW,et al.Pembrolizumab versus docetaxel for previously treated,PD-L1-positive,advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial[J].Lancet,2016,387(10027):1540-1550.[15]Mazieres J,Drilon A,Lusque A,et al.Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations:results from the IMMUNOTARGET registry[J].Ann Oncol,2019,30(8):1321-1328.[16]Zhong H,Zhang X,Tian P,et al.Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy[J].J Immunother Cancer,2023,11(8):e006887.[17]Zhou C,Huang D,Fan Y,et al.Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303):A Phase 3,Open-Label,Randomized Controlled Trial[J].J Thorac Oncol,2023,18(1):93-105.[18]Wang X,Teng F,Kong L,et al.PD-L1 expression in human cancers and its association with clinical outcomes[J].Onco Targets Ther,2016,9:5023-5039.[19]Schoenfeld AJ,Rizvi H,Bandlamudi C,et al.Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas[J].Ann Oncol,2020,31(5):599-608.[20]Daei Sorkhabi A,Zaredini M,Fazlollahi A,et al.The safety and efficacy of tislelizumab,alone or in combination with chemotherapy,for the treatment of non-small cell lung cancer:a systematic review of clinical trials[J].BMC Pulm Med,2023,23(1):495.[21]Zhang Q,Jiao X,Lai X.Clinical Characters and Influence Factors of Immune Checkpoint Inhibitor-related Thyroid Dysfunction[J].J Clin Endocrinol Metab,2023,108(11):2916-2923.[22]Illouz F,Briet C,Rodien P.Immune checkpoint inhibitor-related thyroid dysfunction[J].Ann Endocrinol (Paris),2023,84(3):346-350.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(08):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(08):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(08):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(08):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[5]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(08):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[6]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(08):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[7]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(08):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[8]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(08):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[9]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
　JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(08):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
[10]杨珑静,马洪波,张献全.抗血管生成药物在非小细胞肺癌中的应用及研究进展[J].医学信息,2019,32(08):58.[doi:10.3969/j.issn.1006-1959.2019.08.018]
　YANG Long-jing,MA Hong-bo,ZHANG Xian-quan.Application and Research Progress of Anti-angiogenic Drugs in Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(08):58.[doi:10.3969/j.issn.1006-1959.2019.08.018]

更新日期/Last Update: 1900-01-01